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Diabetic nephropathy involves a renal inflammatory
response induced by the diabetic milieu. Macrophages
accumulate in diabetic kidneys in association with the local
upregulation of monocyte chemoattractant protein-1 (MCP-1);
however, the contribution of macrophages to renal injury and
the importance of MCP-1 to their accrual are unclear.
Therefore, we examined the progression of streptozotocin
(STZ)-induced diabetic nephropathy in mice deficient in MCP-1
in order to explore the role of MCP-1-mediated
macrophage accumulation in the development of diabetic
kidney damage. Renal pathology was examined at 2, 8, 12
and 18 weeks after STZ treatment in MCP-1 intact (þ /þ )
and deficient (/) mice with equivalent blood glucose and
hemoglobin A1c levels. In MCP-1(þ /þ ) mice, the
development of diabetic nephropathy was associated with
increased kidney MCP-1 production, which occurred mostly
in tubules, consistent with our in vitro finding that elements
of the diabetic milieu (high glucose and advanced glycation
end products) directly stimulate tubular MCP-1 secretion.
Diabetes of 18 weeks resulted in albuminuria and elevated
plasma creatinine in MCP-1(þ /þ ) mice, but these aspects of
renal injury were largely suppressed in MCP-1(/) mice.
Protection from nephropathy in diabetic MCP-1(/) mice
was associated with marked reductions in glomerular and
interstitial macrophage accumulation, histological damage
and renal fibrosis. Diabetic MCP-1(/) mice also had a
smaller proportion of kidney macrophages expressing markers
of activation (inducible nitric oxide synthase or sialoadhesin)
compared to diabetic MCP-1(þ /þ ) mice. In conclusion, our
study demonstrates that MCP-1-mediated macrophage
accumulation and activation plays a critical role in the
development of STZ-induced mouse diabetic nephropathy.
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Diabetic nephropathy is the most prevalent cause of end-
stage renal failure worldwide. Despite established conven-
tional therapy of glycemic and blood pressure control, many
patients still develop progressive renal damage,1 suggesting a
need for additional treatments and the identification of
appropriate therapeutic targets.
Macrophages are the major inflammatory cells found in
diabetic kidneys and their accumulation is a recognized feature
in both human biopsies and animal models.2–5 Although
macrophages are known to play a pivotal role in the patho-
genesis of various experimental models of immune-mediated
kidney disease,6,7 their contribution to renal injury in diabetic
nephropathy is unknown. It is not established whether macro-
phages are a major effector of diabetic renal damage, or merely
recruited as a response to injury. Previous studies involving the
use of irradiation4 or administration of mycophenolate8 suggest
some renal protection by reducing macrophages in diabetic
kidneys. However, both these treatments have immunological or
renal effects in addition to macrophage depletion, and cannot be
used for determining the long-term effects of macrophages on
the progression of diabetic nephropathy.
The use of gene knockout mice to target the molecular
mechanisms of macrophage accumulation and activation
may provide a more specific, practicable means of determin-
ing the long-term effects of macrophages on the diabetic
kidney. Macrophage infiltration into any injured tissue
involves their extravascularization mediated by cell adhesion
molecules and chemokines.6 A number of cell adhesion
molecules (ICAM-1, LFA-1, VCAM-1) and chemokines
(OPN, monocyte chemoattractant protein-1 (MCP-1), mi-
gration inhibitory factor, macrophage inflammatory protein-
1 a/b, RANTES) have been shown to be important in
macrophage accumulation and renal injury in models of
nondiabetic kidney damage,6,9 and many of these molecules
are also elevated in diabetic kidneys.5,10 Therefore, the use of
mice deficient in adhesion molecules or chemokines may
allow us to explore the role of macrophages in the
progression of diabetic nephropathy.
MCP-1 is a potent chemokine that is known to affect both
macrophage accumulation and macrophage function.11–13
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MCP-1 increases progressively in diabetic kidneys in animal
models,5,14 and urinary levels correlate with albuminuria in
human diabetic nephropathy.15 In diabetic kidneys, MCP-1
levels appear to be dependent on both the diabetic milieu16
and activation of the renin–angiotensin system.17,18
In the current study, we examine the development of
streptozotocin (STZ)-induced type I diabetic nephropathy in
mice genetically deficient in MCP-1 in order to determine the
role of MCP-1 in promoting macrophage accumulation and
activation in this model, and to establish the importance of
macrophages in the progression of diabetic renal injury.
RESULTS
Tubular MCP-1 production is increased by the diabetic milieu
Tubular cell (NRK52E) secretion of MCP-1 increased in the
presence of high glucose (25 mmol/l) compared to cells
cultured in serum-free media containing a normal physio-
logical level of glucose (5 mmol/l) (Figure 1a). This effect was
not due to osmotic stress because the use of L-glucose as an
osmotic control did not increase MCP-1 levels. Stimulation
of tubular cells with 200 mg/ml bovine serum albumin (BSA)
did not alter MCP-1 secretion compared to media alone;
however, an equivalent concentration of advanced glycation
end product (AGE)–BSA induced a significant increase in
tubular MCP-1 release (Figure 1b).
Induction of diabetes in STZ-treated mice
Administration of STZ resulted in 90% of MCP-1-intact (þ /þ )
mice and 65% of MCP-1-deficient (/) mice developing
overt diabetes (blood glucose 416 mmol/l) after 2 weeks. At
2 weeks, groups of MCP-1-intact and -deficient mice with
equivalent blood glucose were selected for comparing the
progression of diabetic nephropathy. Analysis of mice
killed at 2, 8, 12 and 18 weeks after STZ demonstrated
a similar development of diabetes between MCP-1-intact and
-deficient strains based on equivalent levels of blood glucose
and hemoglobin A1c (HbA1c) at each time point (Figure 2).
Renal expression of MCP-1 increases with the duration of STZ
diabetes
In situ analysis demonstrated that MCP-1 mRNA was not
detectable in normal kidneys or MCP-1-deficient diabetic
kidneys (Figure 3a–d). In comparison, MCP-1 was observed
in some glomerular and tubular cells in MCP-1-intact mice
after 2 weeks of STZ diabetes, but was not detected if these
mice were prevented from becoming diabetic by daily insulin
administration (Figure 3b and c). In diabetic MCP-1-intact
mice, the number of glomerular and tubular cells expressing
MCP-1 mRNA increased progressively with the duration of
disease (Figure 4).
Deficiency of MCP-1 reduces kidney macrophage accumula-
tion and activation in STZ-diabetic mice
Compared to normal mice, there was a three- to four-fold
increase in total kidney leukocytes (CD45þ ) in diabetic
MCP-1(þ /þ ) mice at 18 weeks after STZ treatment.
Further analysis of the diabetic kidneys indicated that almost
all glomerular leukocytes (CD45: 2.8370.20 cells/glomerular
tuft cross-sections (gcs), CD68: 2.5870.53 cells/gcs, CD4:
0.1170.02 cells/gcs, CD8: 0.01770.008 cells/gcs) and inter-
stitial leukocytes (CD45: 492715 cells/mm2, CD68: 475727
cells/mm2, CD4: 16.772.5 cells/mm2, CD8: 0.6770.33 cells/
mm2) were macrophages. Following the onset of diabetes,
increased numbers of kidney macrophages were noted as
early as 2 weeks after STZ in both MCP-1-intact and
-deficient mice (Figure 5a and b). Between 2 and 18 weeks,
the recruitment of glomerular and interstitial macrophages
was more pronounced in MCP-1(þ /þ ) compared to
MCP-1(/) diabetic mice such that macrophage accumu-
lation was reduced by 50–90% in MCP-1(/) mice at week
18. In contrast, numbers of glomerular CD8 cells and
interstitial CD4 and CD8 cells did not change with the
induction of diabetes in either MCP-1(þ /þ ) or (/)
mice. However, glomerular CD4 cells, which were rare in
normal mice (0.02570.035 cells/gcs), did increase fourfold in
diabetic kidneys, but were unaffected by the absence of MCP-1
at any time point (data not shown).
Levels of urine MCP-1 obtained from normal and diabetic
MCP-1-intact mice correlated with number of glomerular
macrophages (r¼ 0.442, P¼ 0.0054) and interstitial macro-
phages (r¼ 0.334, P¼ 0.040) detected by CD68 immunos-
taining.
Macrophage activation was examined at week 18 by two-
color immunostaining on the basis of expression of inducible
nitric oxide synthase (iNOS) and sialoadhesin (CD169). In
MCP-1(þ /þ ) mice, the development of diabetes not only
increased the number of kidney macrophages but also the
percentage of glomerular and interstitial macrophages expres-
sing CD169 and iNOS (Figure 5c and d). In MCP-1(þ /þ )
0
200
400
600
M
CP
-1
(pg
/m
l/2
4 
h/
10
6  
ce
lls
)
D-glucose (mM): 5 5
L-glucose (mM): 0
a b
∗∗ ∗∗
NS
0
200
400
600
SFM BSA AGE–BSA
∗
NS
∗
25
200
Figure 1 | Tubular MCP-1 secretion is increased by the diabetic
milieu. (a) MCP-1 was secreted by NRK52E tubular cells cultured at
normal physiological levels of D-glucose (5 mmol/l). Increasing the
D-glucose to a concentration comparable with the blood glucose
level seen in diabetic mice (25 mmol/l) resulted in increased tubular
MCP-1 secretion. The use of L-glucose as an osmotic control demon-
strated that the increase in tubular MCP-1 detected in the presence of
high glucose was not due to elevated osmotic stress. (b) Stimulation
with 200 mg/ml BSA did not increase tubular secretion of MCP-1
compared to serum-free media (SFM) alone. However, when cells
were incubated in 200 mg/ml AGE–BSA, the tubular secretion of MCP-
1 was significantly enhanced compared to BSA or SFM. Data are
mean7s.d.; n¼ 3; *Po0.05, **Po0.01, NS¼ not significant. Results
were obtained from the means of three separate experiments.
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diabetic kidneys, most glomerular and interstitial macro-
phages expressed CD169 and almost 20% of glomerular
macrophages expressed iNOS; however, very few interstitial
macrophages displayed iNOS expression. In comparison,
MCP-1(/) diabetic kidneys had a reduced percentage of
CD169þ macrophages and their percentage of iNOSþ
macrophages was equal to nondiabetic mice.
Renal injury is attenuated in STZ-diabetic mice deficient in
MCP-1
Urine albumin excretion was normal at the onset of STZ dia-
betes (2 weeks) but increased progressively in MCP-1(þ /þ )
diabetic mice and was threefold greater than normal at 18
weeks after STZ (Figure 6a). In comparison, diabetic MCP-
1(/) mice exhibited no increase in urine albumin
excretion throughout disease, with levels remaining the same
as nondiabetic mice at all time points (Figure 6a).
In the absence of diabetes, renal function assessed as the
plasma creatinine level was similar in MCP-1(þ /þ ) mice
(3171.8 mM) and MCP-1(/) mice (31.371.9 mM) at 26
weeks of age. Compared to nondiabetic animals, plasma
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Figure 2 | Development of diabetes in STZ-treated mice. Groups of MCP-1 intact (þ /þ ) and deficient (/) mice were chosen at 2 weeks
after STZ treatment for equivalent diabetes and were monitored for the continuing development of diabetes at weeks 8, 12 and 18. These
groups were examined for (a) body weight, (b) blood glucose and (c) HbA1c levels and results were compared with age-matched normal MCP-
1(þ /þ ) mice. Data are mean7s.e.m.; n¼ 8–10 for each group.
Figure 3 | Diabetes induces kidney MCP-1 expression. In situ
hybridization indicated that MCP-1 mRNA was absent in (a) a normal
MCP-1(þ /þ ) mouse kidney but was present in the dilated tubules
and some glomerular cells of (b) a diabetic MCP-1(þ /þ ) mouse
kidney at 2 weeks after STZ treatment. In comparison, no MCP-1
mRNA was detected in the kidney of (c) a normoglycemic STZ-treated
MCP-1(þ /þ ) mouse, which had been given insulin to prevent the
onset of diabetes. As expected, MCP-1 mRNA was also absent from
the kidney of (d) a diabetic MCP-1(/) mouse at 2 weeks after STZ
treatment. Original magnification: a–d,  400.
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Figure 4 | Kidney MCP-1 expression increases with the progres-
sion of diabetes in STZ-treated mice. In situ hybridization analysis
of diabetic kidneys from STZ-treated MCP-1(þ /þ ) mice identified
increasing numbers of (a) glomerular cells and (b) tubules expressing
MCP-1 mRNA as the duration of diabetes progressed. Data are
mean7s.e.m.; n¼ 8–10; *Po0.05, **Po0.01, ***Po0.001 vs week 2
after STZ treatment.
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creatinine was elevated in diabetic MCP-1(þ /þ ) mice at 2
weeks of disease and was not different from levels in diabetic
MCP-1(/) mice (Figure 6b). This increase in plasma
creatinine at 2 weeks was due to the development of diabetes
and its impact on the kidney (e.g. hyperfiltration, tubular
dysfunction), because prevention of hyperglycemia with
insulin treatment for 2 weeks prevented this rise in plasma
creatinine (30.771.7 mM) in MCP-1(þ /þ ) mice. Between 2
and 18 weeks of diabetes, MCP-1(þ /þ ) mice showed a
progressive increase in plasma creatinine, whereas the plasma
creatinine in the MCP-1(/) diabetic mice remained
unchanged and was similar to age-matched nondiabetic mice
at 18 weeks after STZ.
The kidney-to-body weight ratio was increased in MCP-
1(þ /þ ) diabetic mice at week 12 (1.1070.05%) and week
18 (0.9170.02%) compared to nondiabetic mice
(0.8070.04%, Po0.05), whereas the ratio in diabetic
MCP-1(/) mice remained at normal levels at week 12
(0.7870.02%) and week 18 (0.8070.04%).
STZ-diabetic mice deficient in MCP-1 have reduced
histological renal injury
In view of the impressive reduction in renal macrophage
counts and albuminuria in the MCP-1(/) diabetic mice,
we further assessed our experimental model for histological
renal damage. Assessment of histological staining at 18 weeks
of disease revealed that glomerular hypertrophy, glomerular
hypercellularity and the percentage of damaged tubules were
reduced in diabetic MCP-1(/) compared to diabetic
MCP-1(þ /þ ) mice (Table 1). Protection from tubular
injury in mice lacking MCP-1 was detected early in the
development of diabetes. At 2 weeks after STZ, there was a
significant increase in the detection of atrophic tubules
in diabetic MCP-1(þ /þ ) mice (0.3970.08% in STZ-treated
vs normal 0.0870.02%, Po0.001), which was reduced
in diabetic MCP-1(/) mice (0.1570.04%, Po0.01)
(Figure 7).
Immunostaining assessment of renal fibrosis found a
significant increase in the expression of glomerular and
interstitial collagen IV and interstitial accumulation of a–
smooth muscle actinþ myofibroblasts in MCP-1(þ /þ )
diabetic mice at 18 weeks, which was largely prevented in
MCP-1(/) diabetic mice (Table 1).
DISCUSSION
Our study demonstrates that induction of kidney MCP-1
production by the development of diabetes is a critical factor
in the progression of kidney macrophage accumulation and
early diabetic renal injury in mice treated with STZ. Kidney
macrophage accrual in MCP-1(þ /þ ) mice increased
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Figure 5 | Macrophage accrual and activation in STZ-treated diabetic kidneys. In comparison to normal nondiabetic mice, immunostaining
identified a significant increase in CD68þ macrophage recruitment in (a) the glomeruli and (b) the interstitium of diabetic kidneys in STZ-
treated MCP-1 (þ /þ ) mice, which progressed with disease duration. At 12 and 18 weeks after STZ, MCP-1(/) mice had markedly less kidney
macrophages than MCP-1(þ /þ ) mice. An increased proportion of kidney macrophages in STZ-treated MCP-1(þ /þ ) mice were found to
express CD169 in (c) the glomeruli and (d) the interstitium compared to normal mice; however, this was significantly reduced in STZ-treated
MCP-1(/) mice. Similarly, a greater percentage of (e) glomerular and (f) interstitial macrophages were found to express iNOS in STZ-treated
MCP-1(þ /þ ) mice compared to normal mice, whereas the percentage of macrophages expressing iNOS in STZ-treated MCP-1(/) mice
was similar to normal. Data are mean7s.e.m.; n¼ 8–10; *Po0.05, **Po0.01, ***Po0.001 vs normal; #Po0.05, ##Po0.01, ###Po0.001 vs STZ
MCP-1(þ /þ ) mice. gcs= glomerular cross-section.
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progressively with the duration of diabetes and correlated
with renal injury, renal expression of MCP-1 mRNA and urine
MCP-1 levels. Examination of MCP-1(þ /þ ) and (/) mice
with equivalent diabetes found that MCP-1 deficiency
markedly reduced kidney macrophage accumulation and
prevented the development of diabetic nephropathy.
In vitro experiments demonstrated that a high glucose
concentration (25 mmol/l), similar to blood glucose levels
observed in diabetic mice, could induce MCP-1 secretion in
cultured tubular cells, providing evidence that tubular MCP-
1 production in diabetic kidneys could be due to a direct
response to high blood glucose. This is supported by our in
situ hybridization results showing that normalization of
blood glucose with insulin prevents induction of kidney
MCP-1 mRNA in STZ-treated mice. In addition, our in vitro
studies indicate that the formation of advanced glycation end
products due to hyperglycemia can also stimulate tubular
MCP-1 secretion. Therefore, hyperglycemia can directly and
indirectly promote kidney MCP-1 production during the
development of diabetes.
The attenuation of renal injury and fibrosis in diabetic
mice deficient in MCP-1 is associated with a reduction in
kidney macrophage recruitment, which is consistent with the
known function of MCP-1 in vitro and in other animal
models.9 Although macrophage recruitment may be the
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Figure 6 | Renal injury in STZ-treated diabetic mice. (a) The urine
albumin excretion rate (UAER) was similar in normal and diabetic
mice at 2 weeks after STZ treatment. At 12 and 18 weeks after STZ,
the UAER was increased two- to three-fold in diabetic MCP-1(þ /þ )
mice; however, the UAER in diabetic MCP-1(/) mice remained near
normal at these time points. (b) The onset of diabetes resulted in
increased plasma creatinine in STZ-treated MCP-1(þ /þ ) mice at 2
weeks, which was further increased at week 18. In comparison, the
plasma creatinine level in STZ-treated MCP-1(/) mice remained
significantly lower than STZ-treated MCP-1(þ /þ ) mice throughout
the analysis period and was not different from normal animals. Data
are mean7s.e.m.; n¼ 8–10; *Po0.05, **Po0.01, ***Po0.001 vs
normal; #Po0.05, ##Po0.01, ###Po0.001 vs STZ MCP-1(þ /þ ) mice.
Table 1 | Histopathology and renal fibrosis (at week 18 after
STZ)
Normal
MCP-1(+/+)
Diabetic
MCP-1(+/+)
Diabetic
MCP-1(/)
Glomerular volume (mm3 104) 24.571.3 30.671.7a 25.971.0b
Glomerular cellularity (cells/gcs) 31.771.1 44.171.5c 38.071.3a,b
Glomerular collagen IV (% area) 15.370.44 19.270.58c 15.470.63d
Atrophic tubules (%) 0.1170.02 8.8570.46c 3.9870.38c,d
Interstitial collagen IV (% area) 20.770.61 25.371.2c 20.670.27d
Interstitial a-SMA (% area) 1.270.09 7.8271.09c 2.370.24d
Data are mean7s.e.m.
aPo0.01.
bPo0.05.
cPo0.001 vs normal.
dPo0.001 vs diabetic MCP-1(+/+).
gcs, glomerular cross-section; SMA, smooth muscle actin.
Figure 7 | Renal histopathology in STZ-treated diabetic mice.
Histological staining with PAS and hematoxylin shows the normal
kidney structure of (a) a nondiabetic mouse. In comparison, there is
significant damage to the glomeruli (hypertrophy, hypercellularity,
mesangial PAS deposits) and tubules (dilatation, atrophy) in (b) a
diabetic MCP-1(þ /þ ) mouse at 18 weeks after STZ, which is
attenuated in (c) an MCP-1(/) mouse with equivalent diabetes.
Immunostaining for CD68 shows very few macrophages in (d) a
normal mouse kidney, which is markedly increased in (e) the
glomeruli and interstitium of an MCP-1(þ /þ ) mouse kidney at 18
weeks after STZ. In comparison, reduced numbers of kidney
macrophages were detected in (f) an MCP-1(/) mouse with
equivalent STZ-induced diabetes. Immunostaining of a-smooth
muscle actin was detected in kidney vessels in (g) a normal mouse.
Many interstitial cells expressing a-smooth muscle actin were
identified in the diabetic kidney of (h) an MCP-1(þ /þ ) mouse at 18
weeks after STZ, and these cells were markedly reduced in (i) an
MCP-1(/) mouse with the same level of diabetes. Original
magnifications: a–f,  400; g,  250.
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major function of MCP-1 in diabetic nephropathy, it is also
possible that MCP-1 could directly promote damage in
intrinsic kidney cells or that MCP-1 may induce additional
responses such as macrophage activation or the recruitment
and activation of T cells. Previously, we have shown that
MCP-1 does not directly injure tubular cells in vitro,19
suggesting that the pathological actions of MCP-1 in the
kidney are more likely to be indirect. In our current study, we
found evidence that MCP-1 may be contributing to
macrophage activation in diabetic mice. MCP-1(/) mice
had reduced tubular injury compared to MCP-1(þ /þ ) mice
at 2 weeks after STZ when macrophage accumulation was
similarly elevated in both strains. Therefore, we hypothesized
that if MCP-1-dependent tubular injury is due to macro-
phages, there must be a difference in macrophage activity in
the presence of MCP-1 to mediate this effect. Further
examination found that MCP-1(þ /þ ) diabetic kidneys
contained a greater proportion of macrophages expressing
CD169 and iNOS, supporting the concept of increased
macrophage activation in the presence of MCP-1. CD169
promotes macrophage adhesion and is a macrophage marker
of chronic inflammation.20 Its expression on monocytes is
known to increase with monocyte MCP-1 production,21
indicating that MCP-1 may play a functional role in
promoting macrophage expression of CD169 during diabetic
nephropathy. Similarly, MCP-1 is known to induce iNOS and
its product NO in cultured mouse macrophages, and these
molecules are considered to be markers of macrophage
activation.12,22 Macrophage production of NO is thought to
contribute to oxidative stress and renal injury during diabetes
by promoting protein nitrosylation; however, this remains
controversial.23–25 Whether or not T cells play a role in
diabetic nephropathy remains to be determined. Most forms
of renal injury that are T-cell dependent exhibit similar
increases in the kidney accumulation of macrophages and
T-cells;6 however, in diabetic nephropathy, the resident
numbers of kidney T cells are virtually unchanged, whereas
kidney macrophages increase progressively with disease. In
our study, we found that MCP-1 deficiency had no impact on
the recruitment of CD4þ and CD8þ T cells. However, their
presence in diabetic kidneys, although small, does not rule
out that MCP-1 may have an effect on T-cell activity. Indeed,
in vitro studies have shown that MCP-1 can regulate T-cell
differentiation,26 which may contribute to renal injury
directly or indirectly by enhancing macrophage activation.
In this study, we showed that MCP-1 is a major contributor
to macrophage recruitment in mouse diabetic kidneys;
however, its absence did not totally prevent macrophage
accumulation. Other macrophage chemokines, such as
osteopontin, migration inhibitory factor and RANTES, are
also expressed by renal cells during diabetes5,10 and may be
involved in macrophage recruitment. In addition, diabetic
kidneys produce increased levels of macrophage colony
stimulating factor, which can increase macrophage numbers
by inducing local proliferation.5,27 Although MCP-1 deficiency
did not entirely abrogate macrophage accrual, its effect was
sufficient to prevent the development of diabetic renal injury.
This suggests that total macrophage blockade may not be
necessary for preventing nephropathy and it may be the state
of macrophage activation, which is most important for
progressive renal injury. Indeed, maintaining some kidney
macrophages may be beneficial to normal renal health by
preserving immune surveillance and phagocytic clearance.6
This study supports the growing evidence that macrophages
are key mediators of renal damage in diabetic nephropathy.
Elements of the diabetic milieu can promote macrophage
recruitment by inducing renal expression of MCP-1 and cell
adhesion molecules, and can stimulate macrophage responses
that cause renal injury. In vitro studies have demonstrated that
AGEs induce macrophage secretion of nitric oxide, reactive
oxygen species, tumor necrosis factor-a and interleukin-1,28–31
which promote inflammation and tissue damage. In addition,
macrophages stimulated with high glucose or AGEs can
promote renal fibrosis through the secretion of fibroblast
growth factors (interleukin-1, platelet derived growth
factor)28,32 and active transforming growth factor-b1.33 There-
fore, macrophages can contribute to the progression of
diabetic nephropathy through multiple mechanisms.
In summary, this study has demonstrated that MCP-1-
mediated macrophage accumulation and activation is a
critical mechanism in the development of early diabetic
nephropathy in STZ-treated mice. As upregulation of kidney
MCP-1 is a feature of human diabetic renal injury associated
with macrophage recruitment and disease progression,
neutralizing MCP-1 activity should be viewed as an
important therapeutic goal in the treatment of diabetic
nephropathy.
MATERIALS AND METHODS
Animal model
Mice genetically deficient in MCP-134 were backcrossed 8 times onto
the C57BL/6J strain and compared with MCP-1-intact C57BL/6J
mice. Both strains were maintained on a normal diet under standard
animal house conditions. To induce diabetes, MCP-1(þ /þ ) and
(/) male mice at 8 weeks of age were given intraperitoneal
injections of STZ (Sigma-Aldrich, St Louis, MO) at 125 mg/kg/day
for 2 consecutive days.28 This was the minimum dose of STZ
required to induce overt diabetes (blood glucose 416 mmol/l) in at
least 50% of MCP-1(/) mice at 2 weeks after administration.
Blood glucose was measured via tail vein sampling at specified times
(between 0900 and 1000 hours) on alert, nonfasted animals
(Medisense glucometer, Abbott Laboratories, Bedford, MA). Groups
of MCP-1(þ /þ ) and (/) diabetic mice with equivalent blood
glucose (2573 mmol/l) were selected at week 2 (n¼ 8–10) and
monitored until being killed at 2, 8, 12 or 18 weeks after STZ in
order to evaluate kidney macrophage accumulation and renal injury.
HbA1c was determined from cardiac blood when animals were
killed. Groups of nondiabetic MCP-1(þ /þ ) mice (n¼ 10) were
assessed for blood glucose and albuminuria and then killed when
age-matched to week 2 STZ-treated mice (10 weeks of age) and week
18 STZ-treated mice (26 weeks of age) to obtain control tissue and
blood. Analysis was also performed on nondiabetic MCP-1(/)
mice (n¼ 6) killed at 26 weeks of age. In addition, tissue and blood
samples were also collected from MCP-1(þ /þ ) mice (n¼ 5) at 2
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weeks after STZ, which were prevented from developing hypergly-
cemia by twice daily subcutaneous administration of 0.5 U isophane
insulin (Protophane, Novo Nordisk, Sydney).
At 12–18 weeks, a minority of mice in each diabetic group
(10–15%) began showing a progressive weight loss associated with
extreme hyperglycemia (blood glucose 430 mmol/l) and were given
isophane insulin to prevent further weight loss while maintaining
diabetes.28
Biochemical analysis
Urine was collected from mice housed in metabolic cages for 18 h
(between 1600 and 1000). Whole blood was collected in the presence
of heparin via cardiac puncture of anaesthetized mice. HbA1c levels
and plasma creatinine were analyzed by the Department of
Biochemistry at the Monash Medical Centre. Urine albumin was
measured by the ELISA kit (Bethyl Laboratories, Montgomery, TX).
Antibodies
Antibodies used in this study were as follows: rat anti-mouse CD45
(M1/9.3.4); rat anti-mouse CD68 (FA-11, Serotec, Oxford, UK); rat
anti-mouse CD4 (GK1.5); rat anti-mouse CD8 (YTS169.4); rat anti-
CD169 (Serotec); goat anti-mouse collagen IV (Santa Cruz
Biotechnology, Santa Cruz, CA); rabbit anti-iNOS (Santa Cruz
Biotechnology) and fluorescein-conjugated anti-a–smooth muscle
actin (1A4, Sigma). Isotype-matched irrelevant IgGs were used as
negative controls. Noncommercial antibodies were produced by cell
culture of hybridomas obtained from the American Tissue Culture
Collection (ATCC, Manassas, VA).
Renal pathology
Formalin-fixed kidney sections (2mm) were stained with periodic
acid Schiff ’s (PAS) reagent and hematoxylin. Digital images of
glomeruli and interstitial areas were obtained from microscopy
(magnification  400). Glomerular cellularity was determined by
counting the cell nuclei in 20 hilar gcs per animal. Glomerular
volume was calculated by measuring the glomerular tuft area with
computer image analysis. The percentage of atrophic tubules
(dilatation, cell loss, necrosis) was assessed by scoring 400 renal
cortical tubules per kidney in randomly selected microscopic fields.
All scoring was performed on blinded slides.
In situ hybridization
cDNA fragments of rat MCP-1 (407 bp) were amplified by reverse
transcription polymerase chain reaction and cloned into the
pMOSBlue vector (Amersham Pharmacia Biotech, Sydney, Austra-
lia). Sense and antisense riboprobes for MCP-1 were labelled with
digoxigenin (DIG)-UTP using a T7 RNA polymerase kit (Roche
Biochemicals, Mannheim, Germany). DIG-labelled antisense cRNA
probes were used to detect MCP-1 in formalin-fixed tissue sections
by in situ hybridization.5
Immunohistochemistry staining
Immunoperoxidase staining for leukocytes (CD45, CD68, CD4,
CD8), macrophages expressing iNOS (iNOSþ /CD68þ ) or
CD169 (CD169þ /CD68þ ), and collagen IV was performed on
paraformaldehyde-lysine-periodate fixed kidney sections (5mm).
Sections were incubated for 20 min each with 0.6% hydrogen
peroxide followed by avidin and biotin block (Vector Laboratories,
Burlingame, CA) and 20% normal sheep serum. Sections were then
incubated overnight at 41C with 5 mg/ml of primary antibody in 1%
BSA. Thereafter, sections were incubated sequentially with biotiny-
lated goat anti-rat IgG (1:200, Vector Laboratories) or biotinylated
rabbit anti-goat IgG (1:200, Zymed, San Francisco, CA) for 45 min
followed by avidin–biotin–peroxidase complex (ABC Kit, Vector
Laboratories) for 45 min and developed with diaminobenzidine
(Sigma). For evaluating macrophages expressing iNOS or CD169,
tissue sections that were immunostained for CD68 were microwave-
treated to retrieve antigens, prevent antibody crossreactivity and
inactivate endogenous alkaline phosphatase.35 Following microwave
treatment, sections were incubated with 20% normal sheep
serum/5% BSA (20 min) and then with rabbit anti-iNOS overnight
at 41C (1:100, Santa Cruz) or rat anti-mouse CD169 (1:200, Serotec)
in 1% BSA. Sections labelled with iNOS antibody were then
incubated at room temperature for 1 h with alkaline phosphatase-
conjugated sheep anti-rabbit IgG (1:50, Dako) and developed
with Fast Blue BB salt (Sigma).5 Sections labelled with CD169
antibody were incubated sequentially with avidin, biotin, biotiny-
lated goat anti-rat IgG, avidin–biotin–alkaline phosphatase
complex (Vector Laboratories) and were then developed with Fast
Blue BB salt.
Quantitation of immunohistochemistry and in situ
hybridization
Immunostained glomerular cells (leukocytes, iNOS, CD169) and
glomerular cells expressing MCP-1 mRNA were counted at high
magnification ( 400) in 20 gcs per animal. Immunostained
interstitial cells (leukocytes, iNOS, CD169) were counted in 25
consecutive high-power ( 400) interstitial fields (representing
30–40% of kidney cortex in the cross-section) by means of
a 0.02 mm2 graticule fitted in the eyepiece of the microscope
and expressed as cells/mm2. Collagen IV and a-smooth muscle
actin expressions were assessed as percent area stained within
the glomerular tuft or the cortical interstitium by image
analysis software (Image Pro Plus, Media Cybernetics, CA). The
percentage of tubules expressing MCP-1 mRNA was assessed by
scoring 400 renal cortical tubules per kidney cross-section in
randomly selected microscopic fields. All scoring was performed on
blinded slides.
Analysis of MCP-1 production by tubular epithelial cells
Proximal tubular epithelial cells (NRK52E) were seeded into 24-well
tissue culture plates at 1 105cells/well in low-glucose Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal calf serum
(FCS) and allowed to adhere overnight. The next day, medium was
replaced with 1% FCS/DMEM and cells were cultured for 24 h. The
following day, when cells were confluent, media were replaced with
serum-free media containing insulin-transferrin-selenium supple-
ment (ITS, Invitrogen) and either 5 mmol/l D-glucose (low glucose),
25 mmol/l D-glucose (high glucose), 5 mmol/l D-glucose and
20 mmol/l L-glucose (osmotic control), control–BSA (200 mg/ml)
or AGE–BSA (200 mg/ml). After incubation for 24 h, the cell
supernatant was collected and assessed for MCP-1 content by the
ELISA kit (Pharmingen, San Diego, CA). The cell number in each
well was counted using a hemacytometer (Reichert, Buffalo, NY).
Data were collected from three separate experiments.
To prepare AGE–BSA, 4 mM BSA was mixed with an equal
volume of 1 M D-glucose and filtered (0.2 mm). This solution was
then incubated in the dark at 371C for 12 weeks under sterile
anaerobic conditions. Control BSA was made by the same procedure
without D-glucose. These preparations were purified to remove
endotoxin as previously described.28
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Statistical analysis
Statistical differences between two groups were analyzed by the
unpaired Student’s t-test (parametric data) or the Mann–Whitney
U-test (nonparametric data), and differences between multiple
groups of data were assessed by one-way analysis of variance using
either Bonferroni’s or Tukey’s multiple comparison test. Correlation
analyses were performed using Pearson’s coefficient (parametric
data) or Spearman’s coefficient (nonparametric data). Data were
recorded as the mean7s.e. and values of Po0.05 were considered
significant. All analyses were accomplished using GraphPad Prism
3.0 (GraphPad Software, San Diego, CA).
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